News
![3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow: https://g.foolcdn.com/editorial/images/757049/vertex-sign.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0g3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cea13c0f11fba85605e95cc9baa34dce01ec4a12/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/vertex-sign.png?locale=us)
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals
![AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why: https://g.foolcdn.com/editorial/images/758830/person-working-in-pharmacy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG43YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b47b13d30cfea6affddc3c03086600081c7d1e1f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-working-in-pharmacy.jpg?locale=us)
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings.
When it was clear a few years ago that
![2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street: https://g.foolcdn.com/editorial/images/759267/growth-curve.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUw2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--df02bdbf724ffe04ede22eb47ed35f41cad34f09/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/growth-curve.jpg?locale=us)
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport
![AT&T Stock Is a Buy for This Reason: https://g.foolcdn.com/editorial/images/758916/building-with-_att-logo-on-front_att.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEQ2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--80f1f5098c045df02e90e4b44004c4f3cb7c70ff/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/building-with-_att-logo-on-front_att.jpg?locale=us)
AT&T Stock Is a Buy for This Reason
The last few years have been a miserable time to own AT&T (NYSE: T) stock. Thanks largely to its dividend income, AT&T investors earned a total return of just 13% over the last five years, a span
![Are Investors Overreacting to Pfizer's Underwhelming Forecast for 2024?: https://g.foolcdn.com/editorial/images/758866/a-frustrated-investor-reviewing-multiple-charts-and-reports.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFg2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--35928bcf22f00ab7a77ce6897c475a80a0235c10/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-frustrated-investor-reviewing-multiple-charts-and-reports.jpg?locale=us)
Are Investors Overreacting to Pfizer's Underwhelming Forecast for 2024?
Pfizer (NYSE: PFE) stock has been in the dumps this year. It is struggling due to declining demand for its COVID products. And it may take some years before its top line starts rising meaningfully
![Editas Just Caught a Break Thanks to Vertex Pharmaceuticals: https://g.foolcdn.com/editorial/images/758926/scientists-lab-testing-blood-draw.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGI2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--10b8ddd90825585a271d2f54ec18566b1715e04b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-lab-testing-blood-draw.jpg?locale=us)
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
It's fair to say that Editas Medicine (NASDAQ: EDIT) is an ailing biotech. Over the past three years, its share price has fallen by 83% as it abandoned parts of its pipeline and laid off staff
![Could CRISPR Therapeutics Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/758864/rich-couple-on-a-boat.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEQ2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--767cfe309f38f3762102129d905ab21ccd57c1fb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/rich-couple-on-a-boat.jpg?locale=us)
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
If you're looking for a stock that has the potential to grow your investment to $1 million, a good move may be to invest in a strong business that's in a fast-growing industry. Gene therapy is an
![Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?: https://g.foolcdn.com/editorial/images/758683/vertex.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGo2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--09b5038c02adacafbd157df278676da99080390f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/vertex.png?locale=us)
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Could the rare-disease-focused biotech Sarepta Therapeutics (NASDAQ: SRPT) one day become a towering, innovative, and profitable growth business, as biopharma Vertex Pharmaceuticals (NASDAQ: VRTX)
![Where Will Regeneron Pharmaceuticals Be in 1 Year?: https://g.foolcdn.com/editorial/images/758512/a-team-of-scientists-reviewing-results-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzc2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dab3e0fdd1a98f71f46bd606336db9412495b391/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-team-of-scientists-reviewing-results-in-a-lab.jpg?locale=us)
Where Will Regeneron Pharmaceuticals Be in 1 Year?
Regeneron Pharmaceuticals (NASDAQ: REGN) is a growing biotech company that generates a ton of free cash flow. Over the years, it has obtained approval or authorization for 12 medicines. Its strong
![Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?: https://g.foolcdn.com/editorial/images/758888/a-person-delivering-a-presentation-getty.jpg](https://www.sharewise.com/rails/active_storage/blobs/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0g1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e9c435a82c770ae966a499d236620b800dcd5ee1/a-person-delivering-a-presentation-getty.jpg?locale=us)
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
Investors looking for stocks that can make dramatic gains fairly quickly got what they wanted from CRISPR Therapeutics (NASDAQ: CRSP) this year. The stock is up more than 60% in 2023 after the
![Valbiotis announces the success of its €15 M capital increase: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
Valbiotis announces the success of its €15 M capital increase
![Is the Vanguard Information Technology Index Fund the Best Tech ETF?: https://g.foolcdn.com/editorial/images/759001/idea.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenY1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--734c4f7faf1456bd18af55fc3d07cab69b9ad6e8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/idea.jpg?locale=us)
Is the Vanguard Information Technology Index Fund the Best Tech ETF?
Technology has been a dominant force in the stock market for the last two decades. Some of the world's most valuable companies, such as Nvidia, Meta Platforms, and Advanced Micro Devices, belong to
![Better Growth Stock: AbbVie vs. Abbott Laboratories: https://g.foolcdn.com/editorial/images/758510/doctor-showing-patient-a-chart.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBejM1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b28e585a4e349a62e4008c1299baec0d23180000/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-showing-patient-a-chart.jpg?locale=us)
Better Growth Stock: AbbVie vs. Abbott Laboratories
Drugmaker AbbVie (NYSE: ABBV) spun off from Abbott Laboratories (NYSE: ABT) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue
![The Top Healthcare Stocks to Buy With $100: https://g.foolcdn.com/editorial/images/758297/physician-talking-to-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBei81YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4dd42755889a4f24ba5c812439cc7708eed1f131/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-talking-to-patient.jpg?locale=us)
The Top Healthcare Stocks to Buy With $100
How much money does one need to start investing in stocks? $1 million? $10,000? The truth is, even a relatively modest sum of $100 is enough to get started for two reasons. First, nowadays, it isn't
![Is AT&T a Better Income Vehicle Than This High-Yield Vanguard Dividend ETF?: https://g.foolcdn.com/editorial/images/758969/passive-income.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXo1YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b8d491de0f487ab715f0c7b3861c83b376a16798/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/passive-income.jpg?locale=us)
Is AT&T a Better Income Vehicle Than This High-Yield Vanguard Dividend ETF?
Investing in stocks requires careful analysis of the potential risks and returns. One way to evaluate a stock is to consider how it fits into your portfolio. For example, do you want a stock that
![6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy: https://g.foolcdn.com/editorial/images/758499/scientists-studying-dna.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd241YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e401e9f9cd9c77e3cc1dd97a15c8320a51192385/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-studying-dna.jpg?locale=us)
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy
December has been a big month for CRISPR Therapeutics (NASDAQ: CRSP). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment
![Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases: https://mms.businesswire.com/media/20231221296013/en/1647007/5/Almirall_HQ_in_Barcelona.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0w0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--72b397537fc7865b79e661e5e9cf7b587fd4fb5b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Almirall_HQ_in_Barcelona.jpg?locale=us)
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases
Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics,
![Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock: https://g.foolcdn.com/editorial/images/758640/dna-on-monitor-scientists.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVA0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c2625e119ed9ef4032ecea2146fd4e79b5fe594/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-on-monitor-scientists.jpg?locale=us)
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock
"The thrill of victory and the agony of defeat."
That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR
![Is Vertex Pharmaceuticals Sitting on a Gold Mine?: https://g.foolcdn.com/editorial/images/758783/gettyimages-two-researchers-work-in-a-lab.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNm40YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a0da424ffd22e96677a6fa841ca69b0244b7778c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-two-researchers-work-in-a-lab.jpg?locale=us)
Is Vertex Pharmaceuticals Sitting on a Gold Mine?
Vertex Pharmaceuticals (NASDAQ: VRTX) has brought in billions of dollars in earnings over time thanks to its leadership in the market for cystic fibrosis (CF) treatment. And along with partner
![This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know: https://g.foolcdn.com/editorial/images/758429/nvidia-headquarters-with-grey-nvidia-sign-in-front-with-nvidia-logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1Q0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--286303723e7ccf20cb8fcae5f241cdc4a03f2629/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/nvidia-headquarters-with-grey-nvidia-sign-in-front-with-nvidia-logo.png?locale=us)
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know
In late November, Roche's (OTC: RHHBY) subsidiary Genentech and the chipmaker Nvidia (NASDAQ: NVDA) agreed to collaborate on developing new medicines using artificial intelligence (AI) over the next
![Better Dividend Stock: Pfizer or British American Tobacco?: https://g.foolcdn.com/editorial/images/758771/piggybank.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXIzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--697fff1ca15d9c827ac6b2fea1830ca80f8f2694/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/piggybank.jpg?locale=us)
Better Dividend Stock: Pfizer or British American Tobacco?
Dividend stocks offer attractive features for income and growth investors alike. On the income side, many blue chip dividend stocks sport higher yields than those of risk-free assets such as the
![Want $1,500 in Dividend Income in 2024? Invest $25,000 in These 3 Top Income Stocks: https://g.foolcdn.com/editorial/images/758508/a-person-smiling-and-reviewing-their-finances.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNUQzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1cbb917e785009b568e11f2a45559e68b0090653/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-smiling-and-reviewing-their-finances.jpg?locale=us)
Want $1,500 in Dividend Income in 2024? Invest $25,000 in These 3 Top Income Stocks
Dividend income can boost your overall returns, and also provide you with some recurring cash flow for your portfolio. That's a good thing, because it means you don't have to sell your investments
![3 Stocks Near Multiyear Lows That Could Bounce Back in 2024: https://g.foolcdn.com/editorial/images/758501/analyst-looking-at-charts.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0QzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9b375a6728ded57505b845081eabb4f50d2904dd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/analyst-looking-at-charts.jpg?locale=us)
3 Stocks Near Multiyear Lows That Could Bounce Back in 2024
When a company underperforms, the markets sometimes have a tendency to overreact. An earnings miss or a guidance cut can at times be enough to lead to a significant sell-off, even if the underlying
![3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow: https://g.foolcdn.com/editorial/images/758605/investors-look-at-tablet-outside.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEwzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a530481e1f80216f50f5db9d1a7bd13d16ff701e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investors-look-at-tablet-outside.jpg?locale=us)
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
CRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The company and partner Vertex Pharmaceuticals delivered positive results from clinical trials of their
![Why Pfizer Stock Is Bouncing Back: https://g.foolcdn.com/editorial/images/758787/1-glowing-green-stock-arrow-climbs-on-a-stock-screen.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzMzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--685bb651efcde483e1c9e37bb301e07188e3c9d7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/1-glowing-green-stock-arrow-climbs-on-a-stock-screen.jpg?locale=us)
Why Pfizer Stock Is Bouncing Back
For the third day in a row, shares of big pharma bellwether Pfizer (NYSE: PFE) are heading higher -- which is kind of curious. Just last week, Pfizer issued downbeat guidance for the year ahead. But